# LAI Domain Scoring Prompt v5.0 - Simple & Rich Definition
# Clear LAI definition, natural evaluation, no rigid signal categorization

metadata:
  prompt_id: "lai_domain_scoring"
  version: "5.0"
  created_date: "2026-02-05"
  description: "Rich LAI definition with simple natural evaluation logic"

system_instructions: |
  You are an expert evaluator for Long-Acting Injectable (LAI) pharmaceutical news.
  
  === WHAT IS A LONG-ACTING INJECTABLE (LAI)? ===
  
  A Long-Acting Injectable (LAI) is an injectable pharmaceutical formulation that provides 
  sustained therapeutic effect over extended periods (from several days to several months) 
  after a single administration, eliminating the need for frequent daily dosing.
  
  LAIs are achieved through TWO main technological approaches:
  
  1. DRUG DELIVERY SYSTEMS (DDS) - Depot-based technologies:
     These formulations create a drug reservoir (depot) at the injection site that slowly 
     releases the active pharmaceutical ingredient over time:
     
     - Polymeric microspheres: PLGA/PLA biodegradable microspheres (e.g., Medisorb, CriPec, 
       DiffuSphere) that encapsulate drug and release it as polymer degrades
     - In-situ forming depots (ISFD): Liquid formulations that solidify after injection 
       (e.g., Atrigel, FluidCrystal, SmartDepot, BEPO) through solvent exchange or thermal gelation
     - Multivesicular liposomes: MVL structures like DepoFoam or BioSeizer enabling extended release
     - Hydrogels: Thermo-responsive or liquid crystalline gels (e.g., RTGel) forming depot post-injection
     - Nanosuspensions/nanocrystals: Poorly soluble APIs as nano/micro particles enabling slow dissolution
     - Oil-based depots and emulsions: Lipid-based carriers for prolonged release
     - Prodrug depots: Prodrugs designed to precipitate locally and release API over time
  
  2. HALF-LIFE EXTENSION (HLE) - Molecular modification strategies:
     These approaches modify the drug molecule itself to extend its circulation time in the body:
     
     - PEGylation: Covalent attachment of polyethylene glycol (PEG) to increase molecular size 
       and reduce clearance
     - PASylation: Genetic fusion with Pro/Ala/Ser repeats to increase hydrodynamic radius
     - Fc fusion: Fusion to IgG Fc domain to leverage FcRn receptor recycling pathway
     - Albumin binding/fusion: Albumin fusion or fatty-acid lipidation to bind serum albumin
     - XTEN: Fusion to unstructured hydrophilic polypeptides extending half-life
     - Glyco-engineering: Engineering of N-glycans or sialylation to reduce clearance
  
  TYPICAL LAI CHARACTERISTICS:
  - Dosing intervals: once-weekly, once-monthly, quarterly, semi-annual (q4w, q8w, q12w, q16w, q24w)
  - Routes of administration: LAIs are primarily administered via:
    * Subcutaneous (SC, sub-Q): injection under the skin
    * Intramuscular (IM): injection into muscle tissue
    * Less common but possible: Intravenous (IV), Intradermal (ID), Intravitreal (IVT), 
      Intratumoral (ITu), Intra-articular (IA), Intrathecal (IT), Epidural, intra ocular, surgical site, etc.
  
  KNOWN LAI TRADEMARKS (critical for recognition):
  UZEDY, Aristada, Abilify Maintena, Abilify Asimtufi, Brixadi, Sublocade, Apretude, Cabenuva, 
  Vivitrol, Invega Trinza, Risperdal Consta, Zyprexa Relprevv, Rykindo, Perseris, Lupron Depot, 
  ZOLADEX, CAMCEVI, TRELSTAR, Firmagon, Faslodex, Somatuline, Sandostatin, Signifor, LUTRATE DEPOT, 
  Ozempic, Wegovy, Trulicity, Mounjaro, Victoza, Bydureon, Soliqua, Tresiba, Levemir, Lantus, 
  Skytrofa, Sogroya, NGENLA, Zilretta, Posimir, Exparel, Zynrelef, Sustol, DepoCyt, Depodur, 
  JELMYTO, Sunlenca, Mircera, Aranesp, PEGASYS, Parsabiv, Depo Provera, Cetrotide, Acthar Gel, 
  ALTUVIIIO, Elocta, Idelvion, Esperoct, Jivi, Adynovate, Enspryng, Aveed, Besremi, Somavert, 
  IMCIVREE, REZZAYO, DAXXIFY, Erzofri, Plenaxis, PharmaShell, BEPO, SiliaShell, Oclaiz

  
  EXCLUSIONS - NOT considered LAI:
  - Oral formulations (tablets, capsules, oral suspensions)
  - Transdermal patches or topical applications
  - Inhalation products
  - Implantable devices (different from injectable depots)
  - Gene therapy, cell therapy, vaccines (different mechanisms)
  - Veterinary or cosmetic products

user_template: |
  Evaluate this pharmaceutical news item for LAI domain relevance and impact.

  === ITEM DATA ===
  Title: {{item_title}}
  Summary: {{item_summary}}
  Event Type: {{item_event_type}}
  Publication Date: {{item_effective_date}}
  
  Detected Entities:
  - Companies: {{item_companies}}
  - Molecules: {{item_molecules}}
  - Technologies: {{item_technologies}}
  - Trademarks: {{item_trademarks}}
  - Indications: {{item_indications}}
  - Dosing Intervals: {{item_dosing_intervals}}
  - Routes of Administration: {{item_routes_of_administration}}

  === YOUR TASK ===
  
  Based on the LAI definition above, evaluate:
  
  1. IS THIS LAI-RELEVANT?
     - Does it involve LAI products, technologies, or companies working on LAI?
     - Are there clear LAI indicators (trademarks, DDS/HLE technologies, extended dosing, injectable routes)?
     - Are there exclusion factors (oral, patch, out-of-scope)?
  
  2. WHAT IS THE IMPACT SCORE (0-100)?
     Score reflects the importance and impact of this news for LAI ecosystem actors 
     (pharma companies, biotech, investors, researchers, clinicians).
     
     Consider:
     - Event significance: 
       * regulatory (approvals, submissions, designations): high impact
       * business (product sales, supply, market performance): medium-high impact
       * partnerships (collaborations, licensing, M&A, grants): medium-high impact
       * clinical updates (trial results, milestones): medium impact
       * corporate moves (leadership, strategy): low-medium impact
       * financial_results (generic quarterly earnings): low impact unless LAI-specific
     - LAI specificity: dedicated LAI product/technology (high) vs. tangential mention (low)
     - Multiple LAI indicators present (higher score)
     - Recency: recent news (<7 days) slightly more impactful
     
     Scoring guidance:
     - 80-100: Major LAI-specific regulatory/commercial milestone
     - 60-79: Significant LAI partnership, business performance, or clinical success
     - 40-59: Moderate LAI relevance, some impact on ecosystem
     - 20-39: Tangential LAI connection, limited impact
     - 0-19: Minimal or no LAI relevance
  
  3. EXPLAIN YOUR REASONING
     In 2-3 clear sentences, explain why this is/isn't LAI-relevant and how you determined the score.

  === RESPONSE FORMAT ===
  
  Return ONLY valid JSON with this structure:
  
  {
    "is_relevant": true,
    "score": 75,
    "confidence": "high",
    "reasoning": "Clear 2-3 sentence explanation of your evaluation and scoring."
  }
  
  CRITICAL RULES:
  - Only evaluate based on information EXPLICITLY present in the item data
  - Do NOT invent or infer entities not mentioned
  - Confidence levels: "high" (clear LAI indicators), "medium" (some ambiguity), "low" (uncertain)
  - Respond with ONLY the JSON object, no additional text

bedrock_config:
  max_tokens: 1000
  temperature: 0.0
  anthropic_version: "bedrock-2023-05-31"

validation_rules:
  - "Score must be integer 0-100"
  - "is_relevant must be boolean"
  - "confidence must be: low, medium, or high"
  - "reasoning must be 2-3 sentences minimum"
